[
  {
    "ts": null,
    "headline": "Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q4 2024 Update",
    "summary": "AQR Capital Management's portfolio grew to $77.63B with top stakes in Apple, Nvidia, Microsoft, Amazon and Alphabet. Read here for a portfolio update.",
    "url": "https://finnhub.io/api/news?id=0f9f76ea1dfc19d71fbc8d6eed19477e768ee0f4440a5d4f249cf95c4ca85f2c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743108470,
      "headline": "Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q4 2024 Update",
      "id": 133501439,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "AQR Capital Management's portfolio grew to $77.63B with top stakes in Apple, Nvidia, Microsoft, Amazon and Alphabet. Read here for a portfolio update.",
      "url": "https://finnhub.io/api/news?id=0f9f76ea1dfc19d71fbc8d6eed19477e768ee0f4440a5d4f249cf95c4ca85f2c"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (NYSE:JNJ) Presents Promising Nipocalimab Data At AAN Annual Meeting",
    "summary": "Johnson & Johnson (NYSE:JNJ) experienced an 11% price increase over the last quarter. This movement coincided with several corporate developments, including the presentation of breakthrough research on nipocalimab at the American Academy of Neurology meeting, and the announcement of FDA fast track designations for its treatments. Additionally, the potential acquisition talks of Intra-Cellular Therapies and strong sales figures in Q4 2024 were pivotal in maintaining investor interest. Launches...",
    "url": "https://finnhub.io/api/news?id=b8dcea1b9f069558ff41d6253cc6135d4e44c95e4bf5cf2cd8cb4a6098abfe30",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743096066,
      "headline": "Johnson & Johnson (NYSE:JNJ) Presents Promising Nipocalimab Data At AAN Annual Meeting",
      "id": 133484813,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) experienced an 11% price increase over the last quarter. This movement coincided with several corporate developments, including the presentation of breakthrough research on nipocalimab at the American Academy of Neurology meeting, and the announcement of FDA fast track designations for its treatments. Additionally, the potential acquisition talks of Intra-Cellular Therapies and strong sales figures in Q4 2024 were pivotal in maintaining investor interest. Launches...",
      "url": "https://finnhub.io/api/news?id=b8dcea1b9f069558ff41d6253cc6135d4e44c95e4bf5cf2cd8cb4a6098abfe30"
    }
  },
  {
    "ts": null,
    "headline": "J&J says Rybrevant/Lazcluze outperforms osimertinib OS in Phase 3 study",
    "summary": "Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib showed Rybrevant plus Lazcluze significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations. Median OS is projected to exceed one year beyond the median o",
    "url": "https://finnhub.io/api/news?id=e43793605daa66e2ead114f1a5c374e029595bb1c1e82ee87c22aff57a155397",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743090609,
      "headline": "J&J says Rybrevant/Lazcluze outperforms osimertinib OS in Phase 3 study",
      "id": 133481338,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib showed Rybrevant plus Lazcluze significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations. Median OS is projected to exceed one year beyond the median o",
      "url": "https://finnhub.io/api/news?id=e43793605daa66e2ead114f1a5c374e029595bb1c1e82ee87c22aff57a155397"
    }
  },
  {
    "ts": null,
    "headline": "How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain",
    "summary": "Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a \"wait-and-see\" pattern.",
    "url": "https://finnhub.io/api/news?id=6ddb50eb5b3605adb9a4f9ae65a9a63fbfee3e28e700e07ecba34a73a219e00b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743084784,
      "headline": "How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain",
      "id": 133472278,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a \"wait-and-see\" pattern.",
      "url": "https://finnhub.io/api/news?id=6ddb50eb5b3605adb9a4f9ae65a9a63fbfee3e28e700e07ecba34a73a219e00b"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know",
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=622ab5d7157bd30cd6c271e38d87e54f3890e11bdef99985d7de7e9db86aec0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743080416,
      "headline": "Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know",
      "id": 133481341,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=622ab5d7157bd30cd6c271e38d87e54f3890e11bdef99985d7de7e9db86aec0b"
    }
  },
  {
    "ts": null,
    "headline": "J&J’s NSCLC combo projected to extend survival by one year over Tagrisso",
    "summary": "The Rybrevant and Lazcluze combination reduced the risk of death by 25% compared to AstraZeneca’s Tagrisso.",
    "url": "https://finnhub.io/api/news?id=eda336580f3a4f707c3c5c15d6ce3edfb8a1f94bdef6c205718751305c07332c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743077997,
      "headline": "J&J’s NSCLC combo projected to extend survival by one year over Tagrisso",
      "id": 133468001,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Rybrevant and Lazcluze combination reduced the risk of death by 25% compared to AstraZeneca’s Tagrisso.",
      "url": "https://finnhub.io/api/news?id=eda336580f3a4f707c3c5c15d6ce3edfb8a1f94bdef6c205718751305c07332c"
    }
  },
  {
    "ts": null,
    "headline": "2 Recession-Proof Dividend Stocks to Buy and Hold",
    "summary": "Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are excellent examples along those lines.  Medtronic and Johnson & Johnson provide some of these products and services.  Medtronic is one of the largest medical device companies in the world.",
    "url": "https://finnhub.io/api/news?id=48a8b90dc8e51001b8758d678e78957940831921ceafd37a9be288a32cf221ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743067500,
      "headline": "2 Recession-Proof Dividend Stocks to Buy and Hold",
      "id": 133468003,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are excellent examples along those lines.  Medtronic and Johnson & Johnson provide some of these products and services.  Medtronic is one of the largest medical device companies in the world.",
      "url": "https://finnhub.io/api/news?id=48a8b90dc8e51001b8758d678e78957940831921ceafd37a9be288a32cf221ee"
    }
  },
  {
    "ts": null,
    "headline": "Plaintiffs Double Down On Challenges To PBM Arrangements In Class Action Lawsuits Involving Johnson & Johnson And JPMorganChase",
    "summary": "On March 10, 2024, the plaintiffs filed an amended complaint in a much-followed putative class action lawsuit against Johnson & Johnson alleging that the plan fiduciaries for J&J's group health plan...",
    "url": "https://finnhub.io/api/news?id=39258b36aff3a234bee2e0a9c579aa441f7e8dedee98a1d082d0ff01a22bccf6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743041407,
      "headline": "Plaintiffs Double Down On Challenges To PBM Arrangements In Class Action Lawsuits Involving Johnson & Johnson And JPMorganChase",
      "id": 133463127,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "On March 10, 2024, the plaintiffs filed an amended complaint in a much-followed putative class action lawsuit against Johnson & Johnson alleging that the plan fiduciaries for J&J's group health plan...",
      "url": "https://finnhub.io/api/news?id=39258b36aff3a234bee2e0a9c579aa441f7e8dedee98a1d082d0ff01a22bccf6"
    }
  }
]